Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023
October 26, 2023 at 04:06 pm EDT
Share
Zynex, Inc. provided earnings guidance for fourth quarter and full year of 2023. Fourth quarter 2023 revenue is estimated to be $52.5-$57.5 million, an increase of approximately 13% from Fourth Quarter 2022. Fourth quarter Diluted EPS is estimated to be $0.17-$0.22.
For the year 2023, the company estimated revenue of $189.5-$194.5 million and Diluted EPS of $0.40-$0.45 per share. The revenue range is based on best estimates of labor market conditions and sales rep productivity. Diluted EPS is impacted by increased operating expenses to support ZMS as the Laser-based Pulse Oximetry products are prepared for FDA submission and the fluid monitor is readied for the market.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
ZYNEX, INC. 
